The team be­hind eF­FEC­TOR's SPAC deal is back af­ter go­ing from launch to merg­er in just 4 months

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The folks who suc­cess­ful­ly launched and merged a SPAC ear­li­er this year are back again, this time seek­ing to take an­oth­er part­ner to Nas­daq through the blank-check route.

Fol­low­ing the de­but of eF­FEC­TOR Ther­a­peu­tics, the team be­hind the Lo­cust Walk Ac­qui­si­tion SPAC will em­bark on a new re­verse merg­er at­tempt, ac­cord­ing to an SEC fil­ing. The new SPAC will be called Phoenix Biotech Ac­qui­si­tion, and it is pen­cil­ing in $155 mil­lion for its IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA